|Bid||26.713 x 20000|
|Ask||26.816 x 20000|
|Day's Range||26.255 - 26.255|
|52 Week Range||23.879 - 51.633|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Medicines Company's CEO, Dr. Clive Meanwell, believes that inclisiran can be a very successful drug at a much lower price than Repatha and Praluent.
The Medicines Company (MDCO) needs investors to pay close attention to the stock based on moves in the options market lately.
Will The Medicines Company be willing to charge significantly less than the price currently commanded by Repatha and Praluent?
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
The Parsippany, New Jersey-based company said it had a loss of 42 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
On August 28, 2017, The Medicines Company (MDCO) announced positive data from its Phase 2 trial, ORION-1, evaluating the efficacy of PCSK9 synthesis inhibitor inclisiran.
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
If you are a shareholder in The Medicines Company’s (NASDAQ:MDCO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.
The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.
The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.
It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
The Medicines Company (NASDAQ: MDCO ) announced FDA approval for Vabomere injection to treat adult patients with complicated urinary tract infections. The company said the drug will be made available in ...
The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
Medicines Co. shares surged 2.5% in premarket trade Wednesday on news that the Food and Drug Administration has approved its injection for complicated urinary tract infections, including the kidney infection ...
The Medicines Company (MDCO) and partner Alnylam publish new one-year safety and efficacy data from phase II extension study of Inclisiran for hypercholesterolemia.